Background: Pseudoxanthoma elasticum (PXE) is an inborn disorder of the connective tissue with specific skin, ocular, and cardiovascular disease (CVD) manifestations. Recently, we and others have identified mutations in the gene coding for the ABCC6 transporter in PXE patients with ocular and skin involvement. In the Netherlands, as in the rest of Europe, a particular premature truncation variant ABCC6 (R1141X) was found in a large cohort of PXE patients. Given the association between CVD and PXE, we hypothesized that heterozygosity of this ABCC6 mutation could also confer an increased risk for CVD.
Methods And Results: To assess the relationship between the frequent R1141X mutation in the ABCC6 gene and the prevalence of premature coronary artery disease (CAD), we conducted a case-control study of 441 patients under the age of 50 years who had definite CAD and 1057 age- and sex-matched population-based controls who were free of coronary disease. Strikingly, the prevalence of the R1141X mutation was 4.2 times higher among patients than among controls (3.2% versus 0.8%; P<0.001). Consequently, among subjects with the R1141X mutation, the odds ratio for a coronary event was 4.23 (95% CI: 1.76 to 10.20, P= 0.001).
Conclusion: The presence of the R1141X mutation in the ABCC6 gene is associated with a sharply increased risk of premature CAD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1161/01.cir.0000028420.27813.c0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Atypical angioid streaks in a patient with a monoallelic mutation.
Ophthalmic Genet
December 2024
Department of Ophthalmology, Bascom Palmer Eye Institute, Miami, Florida, USA.
Background: Pseudoxanthoma elasticum (PXE) is characterized by aberrant calcification of elastic tissues throughout the body causing varying degrees of skin, cardiac, and ocular disease. Although PXE is classically regarded as an autosomal recessive disease, recent reports have demonstrated a haploinsufficiency phenotype, in which carriers of monoallelic ATP-binding cassette transporter () gene mutations demonstrate mild manifestations of PXE. In this case report, we describe a patient with a monoallelic mutation and atypical angioid streaks.
View Article and Find Full Text PDFArterial calcification volume is associated with a higher risk of cardiovascular events in pseudoxanthoma elasticum.
Atherosclerosis
January 2025
Department of Vascular Medicine, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands. Electronic address:
Background And Aims: Pseudoxanthoma elasticum (PXE) patients have more arterial calcification due to lower levels of inorganic pyrophosphate, caused by mutations in the ABCC6 gene, but the relation with vascular complications is poorly understood. Because of the slow progressing nature of arterial disease in PXE patients, there is a need for a valid and reliable intermediate endpoint to be used in future clinical trials. Arterial calcification measured on computed tomography (CT) is a promising candidate, if associated with future cardiovascular events.
View Article and Find Full Text PDFPreterm Infant with Generalized Arterial Calcification of Infancy Who Survived Due to Early Diagnosis and Appropriate Treatment with Bisphosphonates: A Case Report.
Children (Basel)
September 2024
Department of Pediatrics, Niigata University Medical and Dental Hospital, Niigata 951-8514, Japan.
Generalized arterial calcification of infancy (GACI) is a rare disease characterized by arterial calcification. GACI is caused by a mutation in the ENPP1 or ABCC6 genes. GACI causes severe hypertension and heart failure, and approximately 50% of patients die within the first 6 months.
View Article and Find Full Text PDFArticle Synopsis
- - Pseudoxanthoma elasticum (PXE) is a rare genetic disorder that leads to issues like retinal problems, skin changes, and hardened arteries, primarily due to calcification beneath the retina, which can cause macular degeneration.
- - Researchers created and studied two specific induced pluripotent stem cell (hiPSC) lines from a PXE patient, focusing on retinal pigment epithelial (RPE) cells to compare their features with those of healthy cells.
- - Initial findings showed that PXE-specific RPE cells have increased pigmentation and poorer barrier and phagocytic functions compared to healthy controls, suggesting factors that contribute to macular degeneration in PXE patients, with further validation needed in more patients.
Novel treatment for PXE: Recombinant ENPP1 enzyme therapy.
Mol Ther
November 2024
Department of Biochemistry and Molecular Biology, Sidney Kimmel Medical College, Jefferson Institute of Molecular Medicine, Thomas Jefferson University, Philadelphia, PA, USA; PXE International Center of Excellence in Research and Clinical Care, Thomas Jefferson University, Philadelphia, PA, USA. Electronic address:
Article Synopsis
- Pseudoxanthoma elasticum (PXE) is a genetic disorder caused by mutations in the ABCC6 gene, leading to impaired levels of a calcification inhibitor, plasma inorganic pyrophosphate (PPi).
- Recent studies show that a treatment called INZ-701 can restore PPi levels and prevent calcification in animal models, while the new enzyme therapy BL-1118 demonstrates effective results in increasing PPi levels and reducing ectopic calcification in mice.
- BL-1118's potential as a second-generation treatment suggests it may provide better efficacy than the ongoing first-generation therapies, with promising results from pharmacokinetic and pharmacodynamic studies.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!